TwitterRSSFacebookDirectors Blog
  Disorders A - Z:   A    B   C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z

Skip secondary menu

Funding News - Rett Syndrome and MECP2

Archive folder iconHistorical Data

  • The information on this page is for historical and research purposes only.
  • For the most current NINDS funding announcements, please see the NINDS list of Active Funding Initiatives or Follow Us on Twitter for the latest funding news.

The National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Mental Health (NIMH), and the National Institute of Child Health and Human Development (NICHD) encourage grant applications for basic and clinical research on Rett syndrome (RTT) and MECP2.

RTT is a severely debilitating neurodevelopmental disorder. Girls with RTT appear to develop normally until about 6 to 18 months of age at which time they enter a period of regression.  Until recently, little progress had been made in understanding the cause of RTT or in developing approaches for its treatment.  However, the demonstration that mutations in the MECP2 gene are responsible for the majority of cases of RTT suggests new avenues for research and therapy development.

For more information, potential applicants should contact Dr. Laura Mamounas, Program Director, Neurogenetics Cluster, NINDS; telephone: 301-496-5745; e-mail:  For a more detailed description of this announcement, visit